EVOKE & EVOKE+ study Posted or Updated on 19 Aug 2024

Have you noticed a change in your memory?

We are recruiting for 2 research studies called Evoke & Evoke+

The purpose of these 3-year studies is to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer’s disease.

This will be done by comparing semaglutide against placebo on the effect on cognition and daily functioning. Seamglutide is already used to treat people with type 2 diabetes.

Who can take part?

You may be able to take part if you are:

• Aged 55 to 85
• Have a diagnosis of Mild cognitive impairment or mild dementia due to Alzheimer’s disease
• Have a study partner who is willing to take part in the study with you

What will happen?

The study will be explained fully to you and your partner, it includes:

• Taking one tablet every day
• Memory tests and questionnaires on how well you manage daily routines
• Blood samples
• 1 brain MRI or CT scan to look at brain structure*
• 1 PET brain scan or a spinal tap to test for amyloid (a protein involved in Alzheimer’s disease)*

*You will have the opportunity to discuss the results of these scans with your study doctor before taking any medication.

To find out more please contact:

Principal Investigator Dr Paul Edison’s team on:

Email: memory@imperial.ac.uk
Phone: 02075941384 / Mobile: 07787 008143; Trials Co-ordinator: Megan Young
Address: Imperial College Memory Research Centre; Imperial College London / Hammersmith Hospital Campus, Level 2, Commonwealth Building, Du Cane Road, London W12 0NN